Sionna Therapeutics To Present Preclinical Data Assessing Combinations Of NBD1 Stabilizers, SION-451 And SION-719, With Complementary Sionna CFTR Modulators, Galicaftor And SION-109, At ECFS 48th European Cystic Fibrosis Conference

Author: Benzinga Newsdesk | May 22, 2025 06:07am

Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that preclinical data assessing combinations of Sionna's nucleotide-binding domain 1 (NBD1) stabilizers, SION-451 and SION-719, with complementary Sionna CFTR modulators, galicaftor (SION-2222) and SION-109, will be featured in an oral presentation at the European Cystic Fibrosis Society's (ECFS) 48th European Cystic Fibrosis Conference, being held June 4-7, 2025 in Milan, Italy.

Posted In: SION